Baxter(US:BAX) Globenewswire·2025-12-11 21:41Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant awareness of the issues [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to October 29, 2025, with a deadline for shareholders to register by December 15, 2025 [3][4]. - Shareholders who purchased shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].